skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

33 Total results for product and free and sample content found

Biomedtracker

Clinical Trials Industry Report

By KNect365 17 Aug 2018

Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.

Topic Clinical trials Clinical trial optimization

Biomedtracker

Biomedtracker 2018 Early Outlook Report

15 Aug 2018

What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

Topic Drug development landscape

Biomedtracker

Biomedtracker Q3 2018 Outlook Report Extract

15 Aug 2018

Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter. 

Topic Drug development landscape

Meddevicetracker

Meddevicetracker Q3 2018 Outlook Report Extract

14 Aug 2018

In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology,  and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.

Pharmaprojects

Microbiome Modulators for Gastrointestinal Disorders In 2018: Market Overview & The Current Phase I Candidates

13 Jul 2018

The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).

Pharmaprojects

2018 R&D Review: 5 Key Takeaways

13 Jul 2018

Welcome to Pharmaprojects’ roundup of key trends in pharmaceutical R&D in 2018, focusing on five key takeaways from our full annual report

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deal trends

Biomedtracker

Q2 Outlook Report Extract

10 May 2018

Get a reliable and accurate view of what’s on the horizon for pharma in the coming quarter. The Biomedtracker Q2 2018 Outlook Report includes essential information, including each drug’s likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.

Topic Drug review

Biomedtracker

BMT Q4 Outlook Report

27 Oct 2017

In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimers Cancer Drug approval

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: